ストックスクリーナーアプリを入手
13.60
4.02%
-0.57
アフターアワーズ：
13.60
前日終値:
$14.17
開ける：
$13.69
24時間の取引高:
5,124
Relative Volume:
0.46
時価総額：
$113.83M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.86%
1か月 パフォーマンス:
+24.89%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$12.77
$13.69
1週間の範囲:
$12.77
$14.30
52週間の値動き範囲:
$9.75
$22.63
Exozymes Inc Stock (EXOZ) Company Profile
EXOZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
13.60 | 117.15M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Exozymes Inc (EXOZ) 最新ニュース
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast - ACCESS Newswire
Exozymes (NASDAQ:EXOZ) Issues Quarterly Earnings Results - MarketBeat
eXoZymes Inc. Reports Q1 2025 Highlights and NCTx Launch - TipRanks
Earnings call transcript: eXoZymes Q1 2025 unveils innovation and market strategy - Investing.com Australia
Exozymes Q1 2025 Earnings Call Transcript - MarketBeat
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today - Stock Titan
eXoZymes develops AI-driven approach to produce rare nutraceutical compound - World Bio Market Insights
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST - Stock Titan
eXoZymes Launches Spin-Out, NCTx, To Unlock A Promising Compound For Gut And Liver Health - SynBioBeta
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health - ACCESS Newswire
Revolutionary Liver Health Compound Finally Achievable: How AI Platform Solved 30-Year Production Challenge - Stock Titan
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - ADVFN
eXoZymes creates AI-engineered enzymes for biomanufacturing - Scientific Computing World
eXoZymes Inc. Introduces 'Exozymes' Terminology in Cover Story of GEN Biotechnology to Advance Cell-Free Biomanufacturing - Nasdaq
Bringing clarity and precision to the cell-free space by introducing exozymes | Daily Guardian - dailyguardian.ca
Bringing clarity and precision to the cell-free space by introducing exozymes - GlobeNewswire
Press Release Distribution & PR Platform - ACCESS Newswire
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vi - Newswire.com
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice - Yahoo Finance
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vi - Tacoma News Tribune
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vic - ACCESS Newswire
EXoZymes Inc. Announces Its Latest Initiative BioClick - MarketScreener
eXoZymes appoints Damien Perriman as Chief Commercial Officer - World Bio Market Insights
eXoZymes Inc. Reports 2024 Progress and IPO Success - TipRanks
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - GlobeNewswire
eXoZymes appoints new chief commercial officer By Investing.com - Investing.com Canada
eXoZymes appoints new chief commercial officer - Investing.com
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewswire
Strategic Win: eXoZymes Taps 20-Year Biotech Leader to Drive Commercial Growth - Stock Titan
MDB Capital's Remarkable Growth: AUM Soars 2100%, New Platform Launch Drives Expansion - Stock Titan
eXoZymes Inc. (EXOZ) reports earnings - Quartz
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 - GlobeNewswire
AI Enzyme Pioneer EXOZ Reveals 2024 Financial Performance: Q4 Earnings Call Details - Stock Titan
New to The Street’s FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese’s The Big Skinny on eXoZymes, and B - The State
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and B - ACCESS Newswire
MDB Capital's 2024 Financial Results: CEO to Reveal Full Year Performance and Strategic Outlook - StockTitan
Who's Winning the AI Data Center Patent Race? New Report Reveals Surprising Leader - StockTitan
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce - Big News Network.com
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle. - Markets Insider
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With C - StreetInsider
eXoZymes president, chairman Hayat transitions out of roles - MSN
Exozymes Inc (EXOZ) 財務データ
Exozymes Inc (EXOZ) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):